---
title: "Seaport Therapeutics, Inc. (SPTX.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/SPTX.US.md"
symbol: "SPTX.US"
name: "Seaport Therapeutics, Inc."
datetime: "2026-05-01T13:21:05.322Z"
locales:
  - [en](https://longbridge.com/en/quote/SPTX.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/SPTX.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/SPTX.US.md)
---

# Seaport Therapeutics, Inc. (SPTX.US)

## Company Overview

Seaport Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company advancing the development of novel neuropsychiatric medicines. The company develops therapeutic candidates for conditions such as depression and anxiety disorders using its proprietary Glyph technology platform. The Glyph platform is designed to enable oral bioavailability, bypass first-pass metabolism, and reduce liver enzyme elevations or hepatotoxicity and other side effects.

| Item | Detail |
|------|--------|
| Exchange | US Market |
| Website | [www.seaporttx.com](https://www.seaporttx.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| Dividend Yield | 0.00% | - | - | - | - |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/SPTX.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/SPTX.US/norm.md)
- [Related News](https://longbridge.com/en/quote/SPTX.US/news.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**